Bodisen Biotech Reports Unaudited First Quarter Financial Results

Review & Extracts of the Form10Q as required by the Securities & Exchange Commission

Bodisen Biotech, Inc. (the “Company”) (OTC Pink Sheets: BBCZ; London AIM:BODI; website: www.bodisen.com) today announced its first quarter results for the period ended March 31, 2007 which are extracted from the company’s Form 10-Q filed with the SEC.

FIRST QUARTER FINANCIAL & OPERATIONAL HIGHLIGHTS

• Revenues $5.01 million from $10.54 million in the same period of 2006.

• Gross profit increased to $1.99 million from $4.24 million in the same period last year.

• Net Income was a loss of ($1.51) million from a profit of $2.68 million in the same period of 2006.

• Diluted EPS was ($0.08) compared with $0.15 in the same period last year.

• Cash position remains strong at $7.11 million as at 31 March 2007.

Enquiries:

Charles Stanley Securities (Nominated Adviser)

Rick Thompson / Philip Davies / Freddy Crossley - 0207 149 6000

Results of Operations

Three months ended March 31, 2007 compared to three months ended March 31, 2006

Revenue. We generated revenues of $5,008,472 for the three months ended March 31, 2007, a decrease of $5,526,888 or 52.5%, compared to $10,535,360 for the three months ended March 31, 2006. The significant decrease in revenue was due to the negative impacton the company's reputation as a result of Bodisen being delisted by American Stock Exchange and the abnormally cold spring time weather of Shaanxi provincewhich affected cropplantings anddecreased the use of fertilizer.

Gross Profit. We achieved a gross profit of $1,990,222 for the three months ended March 31, 2007, a decrease of $2,246,017 or 53.0%, compared to $4,236,239 for the three months ended March 31, 2006. The significant decrease in gross profit was due to the decreasein our sales revenue. Gross margin (gross profit as a percentage of revenues), slightly decreased, down from 40.2% for the three months ended March 31, 2006, to 39.7% for the three months ended March 31, 2007.

Operating expenses. We incurred operating expenses of $3,521,523 for the three months ended March 31, 2007, a significant increase compared to $778,398 for the three months ended March 31, 2006. The significant increase in our operating expenses is primarily related to an increase in our allowance for bad debts during the three months ended March 31, 2007 of $1,360,277, which resulted from decrease of collections due to the damage to the company's reputation as discussed above. This significant increase in our allowance for bad debts offset the slight decrease in our aggregated selling expenses.

Aggregated selling expenses accounted for $349,014 of our operating expenses for the three months ended March 31, 2007, a decrease of $125,160 or 26.4% compared to $474,174 for the three months ended March 31, 2006. The decrease in our aggregated selling expenses is due to the decrease of transportation expense as a result of the decrease.in sales. General and administrative expenses accounted for the remainder of our operating expenses for the three months ended March 31, 2007, which increased $2,868,285 compared to $304,224 for the three months ended March 31, 2006. The increase in general and administrative expenses is due to an increased in our allowance for bad debts during the three months ended March 31, 2007 of $1,360,277,as discussed above and, to a lesser extent, higher legal fees.

Non Operating Income and Expenses. We had total non-operating income of $21,755 for the three months ended March 31, 2007 compared to total non-operating expense of $775,198 for the three months ended March 31, 2006. Total non-operating income in the first quarter of 2007 included $67,197 of other expenses while in the first quarter of 2006 we had $124,541 of other expenses. Total non-operating income includes interest income of $90,009 for the three months ended March 31, 2007 compared to only $28,063 of interest income for the three months ended March 31, 2006. The increase in the first quarter of 2007 is due to the increase in our cash balance as a result ofthe repayment of a short term loan the company made to non-related parties.Total non-operating income for the three months ended March 31, 2007 also includes interest expense of only $1,057 compared to $678,720 of interest expense for the three months ended March 31, 2006. The majority of the interest expense in the first quarter of 2006 relates to the $5 million note issued December 8, 2005, which was repaid during March 2006.

Net Income (Loss). For the foregoing reasons, we had a net loss of $1,509,546 for the three months ended March 31, 2007 compared to net income of $2,682,643 for the three months ended March 31, 2006. We had a loss per share of $(0.08) for the three months ended March 31, 2007 compared to earnings per share of $0.16 for the three months ended March 31, 2006.

About Bodisen Biotech, Inc.

Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. Ranked the 16th fastest growing company in China by Forbes China in January 2006, the company is headquartered in Shaanxi province and is a Delaware corporation. The company's environmentally friendly ``green'' products have been proven to improve soil and plant quality, and increase crop yields.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

BODISEN BIOTECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)

FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2007 AND 2006

		Three Month Periods Ended March 31,
		2007			2006
		(Unaudited)			(Unaudited)
Net Revenue		$	5,008,472		$	10,535,360
Cost of Revenue			3,018,250			6,299,121
Gross profit			1,990,222			4,236,239
Operating expenses
Selling expenses			349,014			474,174
General and administrative expenses			3,172,509			304,224
Total operating expenses			3,521,523			778,398
Income / (Loss) from operations			(1,531,301	)		3,457,841
Non-operating income (expense):
Other income (expense)			(67,197	)		(124,541	)
Interest income			90,009			28,063
Interest expense			(1,057	)		(678,720	)
Total non-operating income (expense)			21,755			(775,198	)
Net income / (loss)			(1,509,546	)		2,682,643
Other comprehensive income
Foreign currency translation gain / (loss)			641,676			(40,500	)
Unrealized gain (loss) on marketable equity security			(2,497,159	)		2,290,783
Comprehensive Income / (Loss)		$	(3,365,029	)	$	4,932,926
Weighted average shares outstanding :
Basic			18,310,250			17,215,232
Diluted			18,310,250			17,374,691
Earnings per share:
Basic		$	(0.08	)	$	0.16
Diluted		$	(0.08	)	$	0.15

BODISEN BIOTECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2007 AND 2006

		Three Month Periods Ended March 31,
		2007			2006
		(unaudited)			(unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)		$	(1,509,546	)	$	2,682,643
Adjustments to reconcile net income to net cash
provided by (used in) operating activities:
Depreciation and amortization			115,221			103,161
Amortization of debt discounts			-			603,886
Exchange gain			-			124,541
Value of vested option issued to directors			-			7,523
Allowance for bad debts			1,360,277			-
(Increase) / decrease in assets:
Accounts receivable			(1,760,948	)		(4,300,470	)
Other receivable & Loan Receivable			(1,177,348	)		(14,144	)
Inventory			(1,851,263	)		(188,722	)
Advances to suppliers			487,098			1,565,316
Prepaid expense			(2,512	)		-
Other assets			-			765
Increase / (decrease) in current liabilities:
Accounts payable			354,315			724,157
Accrued expenses			1,992			62,910
Net cash provided by (used in) operating activities			(3,982,714	)		1,371,566
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property and equipment			(57,187	)		(43,776	)
Additions to construction in progress			(823,584	)		(349,147	)
Proceeds from other assets			43,583			-
Net cash used in investing activities			(837,188	)		(392,923	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on note payable			-			(5,000,000	)
Proceeds from issuance of common stock			-			26,682,511
Payment of offering costs			-			(2,747,227	)
Proceeds from the exercise of warrants			-			220,160
Net cash provided by financing activities			-			19,155,444
Effect of exchange rate changes on cash and cash equivalents			105,437			(325,238	)
NET INCREASE /(DECREASE) IN CASH & CASH EQUIVALENTS			(4,714,465	)		19,808,849
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD			11,824,327			6,276,897
CASH & CASH EQUIVALENTS, END OF PERIOD		$	7,109,862		$	26,085,746
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid		$	-		$	112,500
Income taxes paid		$	-		$	-

Note Earnings Per Share

Earnings per share for three months March 31, 2007 and 2006 were determined by dividing net income for the periods by the weighted average number of both basic and diluted shares of common stock and common stock equivalents outstanding.

The following is an analysis of the differences between basic and diluted earnings per common share in accordance with Statement of Financial Accounting Standards No. 128, “Earnings Per Share”.

		Three Months Ended March 31,
		2007									2006
								Per									Per
		Loss			Shares			Share			Income			Shares			Share
Basic earnings per share
Net income (loss)		$	(1,509,546	)							$	2,682,643
Weighed shares outstanding						18,310,250									17,215,232
								$	(0.08	)							$	0.16
Diluted earnings per share
Net income (loss)		$	(1,509,546	)							$	2,682,643
Weighed shares outstanding						18,310,250									17,215,232
Effect of dilutive securities
Options						-									89,537
Warrants						-									69,922
						18,310,250									17,374,691
								$	(0.08	)							$	0.15